Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

NCT04025567 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped slow/insufficient accrual.

Conditions

Metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma

Interventions

DRUG: vancomycin

Sponsor

National Cancer Institute (NCI)